Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1932658

Prostate Cancer - Pipeline Review, H2 2011

Description:
Prostate Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Prostate Cancer - Pipeline Review, H2 2011', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. 'Prostate Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Prostate Cancer.
- A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Prostate Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostate Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Prostate Cancer
Prostate Cancer Therapeutics under Development by Companies
Prostate Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Prostate Cancer Therapeutics - Products under Development by Companies
Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Prostate Cancer Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
Sanofi-Aventis
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
Bioniche Life Sciences, Inc.
Genentech, Inc.
Nektar Therapeutics
Pfizer Inc.
SuperGen, Inc.
Taiho Pharmaceutical Co., Ltd.
Cell Therapeutics, Inc.
Progenics Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc.
ENKAM Pharmaceuticals A/S
Exelixis, Inc.
Aduro BioTech
Menarini Group
Celgene Corporation
Bayer AG
Attenuon, LLC
Incyte Corporation
Geron Corporation
Merck KGaA
Access Pharmaceuticals, Inc.
Advaxis, Inc.
Alchemia Limited
Addex Pharmaceuticals
Neuren Pharmaceuticals Limited
Northwest Biotherapeutics, Inc.
Circadian Technologies Limited
Cleveland BioLabs, Inc.
Oncolytics Biotech Inc.
Oncothyreon Inc
OncoVista Innovative Therapies, Inc.
Compugen Ltd.
Osta Biotechnologies Inc.
Patrys Limited
Peregrine Pharmaceuticals, Inc.
Medivation, Inc.
Keryx Biopharmaceuticals, Inc.
ADVENTRX Pharmaceuticals
Telik, Inc.
Transcept Pharmaceuticals, Inc.
Soligenix, Inc.
Poniard Pharmaceuticals, Inc.
Axelar AB
Endocyte, Inc.
Polyphenon Pharma
Omnitura Therapeutics Inc.
Pharminox Limited
Esperance Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Transtech Pharma, Inc.
ImmunoVaccine Technologies Inc.
Welichem Biotech Inc.
Peptron, Inc.
GENova Biotherapeutics, Inc.
Etubics Corporation
TSD Japan, Inc.
BIND Biosciences, Inc.
Ausio Pharmaceuticals, LLC
Errant Gene Therapeutics, LLC
Polaris Group
ImQuest Life Sciences
CytoVac A/S
Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Yervoy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Firmagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acapodene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OGX-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TASQ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDV3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XRP6258 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leuprolide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zaltrap - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prostate Cancer Therapeutics – Drug Profile Updates
Prostate Cancer Therapeutics - Discontinued Products
Prostate Cancer - Featured News
Sep 13, 2011: Bayer To Present New Data On Alpharadin's Pivotal Phase III Study At 2011 ECCO-ESMO Congress
Sep 12, 2011: Oncothyreon Initiates Phase II Trial Of PX-866 In Patients With Prostate Cancer
Sep 07, 2011: Janssen-Cilag Announces Approval Of ZYTIGA In EU For Metastatic Castration-Resistant Prostate Cancer
Sep 06, 2011: OncoGenex Announces Publication Of Phase II Clinical Trial Results Of Custirsen
Sep 02, 2011: Exelixis To Provide Update On Cabozantinib At Stifel Nicolaus Healthcare Conference
Aug 30, 2011: Adamis Begins Phase I/IIa Clinical Prostate Study
Aug 23, 2011: FDA Grants Fast Track Designation To Bayer’s Alpharadin For Castration Resistant Prostate Cancer In Patients With Bone Metastases
Aug 22, 2011: Amgen Announces PDUFA Date For XGEVA Supplemental Biologics License Application
Aug 11, 2011: Advaxis Completes Pre-IND Meeting With FDA On Development Plan For ADXS-PSA
Jul 28, 2011: Bavarian Nordic Announces Publication Of New Article On PROSTVAC And Other Immunotherapies For Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Prostate Cancer, H2 2011
Products under Development for Prostate Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Genzyme Corporation, H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Kyowa Hakko Kirin Co., Ltd., H2 2011
Abbott Laboratories, H2 2011
Amgen Inc., H2 2011
Sanofi-Aventis, H2 2011
Adherex Technologies Inc., H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
Viralytics Ltd., H2 2011
Bioniche Life Sciences, Inc., H2 2011
Genentech, Inc., H2 2011
Nektar Therapeutics, H2 2011
Inovio Biomedical Corporation, H2 2011

List of Figures
Number of Products under Development for Prostate Cancer, H2 2011
Products under Development for Prostate Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1932658

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Wednesday, June 19, 2013
5:27:07 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Prostate Cancer - Pipeline Review, H2 2011

Web Address

http://www.researchandmarkets.com/reports/1932658

Office Code

OC8DIQQMMPUPRU

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 382
Electronic (PDF) - Site License EUR 765
Electronic (PDF) - Enterprisewide EUR 1,147

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Wednesday, June 19, 2013
5:27:07 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)